Multi-drug resistant Acinetobacter baumannii-gram-negative "MRSA" in 21st century

( views:, downloads: )
YU Yun-song(State Key Laboratoryfor Diagnosis and Treatment of Infectious Diseases,the First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310003,China)
Journal Title:
Volume 2, Issue 02, 2009
Key Word:
Acinetobacter baumannii;Muhidrug resislance;Gram-negative bacteria


  • [1]Mendes RE,Bell JM,Tumidgc JD,et al.Emergence and widespread dissemination of OXA-23,-24/40 and -58 carbapenemases among Acinetobacter Asia-Pacific nations:report from the SENTRY Surveillance Program.J Antimicrob Chemother,2009,63(1):55-59.
  • [2]Wang F,Zhu DM,Hu,FP,et al.CHINET 2007 surveillance of bacterial resistance in China.Zhongguo Ganran yu Hualiao Zazhi,2008,8 (5):325-333.(in Chinese)汪复,朱德妹,胡付品,等.2007年中国CHINET细菌耐药性监测.中国感染与化疗杂志,2008,8(5):325-333.
  • [3]Munoz-Price LS,Weinstein RA.Acinewbacter infection.N Engl J Med,2008,358(12):1271-1281.
  • [4]Pcleg AY,Seifert H,Paterson DL.Acinetobacter baumannii:emergence of a successful pathogen.Clin Microbiol Rev,2008,21 (3):538-582.
  • [5]Halstead DC,Abid J,Dowzicky MJ.Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the tigecycline evaluation and surveillance trial.J Infect,2007,55(1):49-57.
  • [6]Zhou H,Yang Q,Yu YS,et al.Clonal spread of imipenemresistant Acinetobacter baumannii among different cities of China.J Clin Microbiol,2007,45(12):4054-4057.
  • [7]Catalano M,Quelle LS,Jeric PE,et al.Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases.J Hosp Infect,1999,42(1):27-35.
  • [8]Simor AE,Lee M,Vearncombe M,et al.An outbreak due to multiresistant Acinetobaeter baumannii in a burn unit:risk factors for acquisition and management.Infect Control Hosp Epidemiol,2002,23(5):261-267.
  • [9]Falagas ME,Bliziotis IA,Siempos Ⅱ.Attributable mortality of Acinetobacter baumannii infections in critically ill patients:a systematic review of matched cohort and case-control studies.Crit Care,2006,10(2):R48.
  • [10]Fournier PE,Vallenet D,Barbe V,et al.Comparative genomics of multidrug resistance in Acinetobacter baumannii.PLoS Genet,2006,2(1):e7.
  • [11]Iacono M,Villa L,Fortini D,et al.Whole-genome pyrosequencing of an epidemic multidrug-resistant Acinetobacter baumannii strain belonging to the Eurnpean clone Ⅱ group.Antimicrob Agents Chemother,2008,52(7):2616-2625.
  • [12]Gales AC,Jones RN,Sader HS.Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli:report from the SENTRY antimicrobial surveillance programme (2001-2004).Clin Microbiol Infect,2006,12(4):315-321.
  • [13]Garnacho-Montero J,Ortiz-Leyba C,Jiménez-Jimenez FJ,et al.Treatment of multidrug-resistant Acinetobacter baumannii ventilatorassociated pneumonia (VAP) with intravenous colistin:a comparison with imipenem-susceptible VAP.Clin Infect Dis,2003,36(9):1111-1118.
  • [14]Koomanachai P,Tiengrim S,Kiratisin P,et al.Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by muhidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital,Bangkok,Thailand.Int J Infect Dis,2007,11(5):402-406.
  • [15]Smolyakov R,Borer A,Riesenberg K,et al.Nosocomial multidrug resistant Acinetobacter baumannii bloodstream infection:risk factors and outcome with ampicillin-sulbactam treatment.J Hosp Infect,2003,54(1):32-38.
  • [16]Corbella X,Ariza J,Ardanuy C,et al.Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by muhiresistant Acinetobacter baumannii.J Antimicrob Chemother,1998,42(6):793-802.
  • [17]Wood GC,Hanes SD,Croce MA,et al.Comparison of ampicillinsulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.Clin Infect Dis,2002,34(11):1425-1430.
  • [18]Betrosian AP,Frantzeskaki F,Xanthaki A,et al.High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from muhidrug-resistant Acinetobacter baumannii.Scand J Infect Dis,2007,39(1):38-43.
  • [19]Navon-Venezia S,Leavitt A,Carmeli Y.High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.J Antimicrob Chemother,2007,59(4):772-774.
  • [20]Gordon NC,Wareham DW.A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline.J Antimicrob Chemother,2009,63(4):775-780.
  • [21]Peleg AY,Potoski BA,Rea R,et al.Acinetobacter baumannii bloodstream infection while receiving tigecycline:a cautioary report.J Antimicrob Chemother,2007,59(1):128-131.
  • [22]Karageorgopoulos DE,Kelesidis T,Kelesidis I,et al.Tigecycline for the treatment of multidrug-resistant (including carbapenemresistant) Acinetobacter infections:a review of the scientific evidence.J Antimicrob Chemother,2008,62(1):45-55.
  • [23]Falagas ME,Rafailidis PI,Kasiakou SK,et al.Effectiveness and nephrotoxicity of colistin monotherapy vs.colistin-meropenem combination therapy for muhidrag-resistant gram-negative bacterial infections.Clin Microbiol Infect,2006,12(12):1227-1230.
  • [24]David MD,Gill MJ.Potential for underdesing and emergence of resistance in Acinetobacter baumannii during treatment with colistin.J Antimicrob Chemother,2008,61 (4):962-964.
  • [25]Saballs M,Pujol M,Tubau F,et al.Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.J Antimicrob Chemnther,2006,58 (3):697-700.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615